NCT06398418View on ClinicalTrials.gov

R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) in Patients With Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

August 1, 2025

Primary Completion Date

April 30, 2027

Study Completion Date

December 31, 2027

Conditions
Solid Tumor, AdultSolid TumorMelanomaBasal Cell CancerSquamous Cell CancerAdenoma
Interventions
DRUG

R-5780

Probiotic

Trial Locations (1)

37203

RECRUITING

Sarah Cannon Research Institute, Nashville

All Listed Sponsors
lead

Rise Therapeutics LLC

INDUSTRY